Thank you for the shout out BIOTECanada!
We are pleased to announce the first patient enrolled in the Phase II/III trial of ST-02, our innovative cancer medication targeting Upper Tract Urethral Carcinoma (UTUC). A rare form of cancer, UTUC affects over 7,000 individuals annually across North America. The clinical trial for ST-02 has begun at the Vancouver Prostate Centre and it is anticipated that five other sites will take part in the study. We plan on enrolling approximately 75 patients in the combined Phase II/III trial and believe that ST-02 may be designated an orphan drug. Read more -> https://lnkd.in/gBh3ugZ5